Skip to main content
IDEAYA Biosciences, Inc. logo

IDEAYA Biosciences, Inc. — Investor Relations & Filings

Ticker · IDYA ISIN · US45166A1025 LEI · 549300ULW08F62IJML11 US Manufacturing
Open in API
Filings indexed 466 across all filing types
Latest filing 2020-06-18 Director's Dealing
Country US United States of America
Listing US IDYA

About IDEAYA Biosciences, Inc.

https://www.ideayabio.com/

IDEAYA Biosciences, Inc. is a clinical-stage precision medicine oncology company focused on the discovery, development, and commercialization of targeted therapeutics for cancer. The company's primary scientific approach is synthetic lethality, an emerging class of precision medicine that targets cancer cells based on specific genetic alterations. IDEAYA develops potential first-in-class and best-in-class therapies for patient populations selected using molecular diagnostics. Its integrated platform combines capabilities in target and biomarker discovery with the development of small molecule and protein degrader therapeutics to address unmet needs in cancer treatment.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2020-06-18 English
FORM 4
Director's Dealing
2020-06-18 English
FORM 4
Director's Dealing
2020-06-18 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock by IDEAYA Biosciences, Inc. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and other related disclosures. The presence of terms like 'prospectus supplement,' 'public offering price,' 'underwriting discounts,' and references to securities laws and SEC registration indicate this is a capital raising document. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is not an annual or quarterly report, audit report, or earnings release, nor is it a regulatory filing or announcement of a report publication. Therefore, the correct classification is CAP with high confidence.
2020-06-16 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 16, 2020, reporting the submission of matters to a vote of security holders at the company's 2020 Annual Meeting of Stockholders. It details the voting results for two proposals: election of a director and ratification of the independent auditor. The document is short (3980 characters) and focuses solely on the voting results from the Annual Meeting. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at any general meeting. It is not a full Annual Report, proxy statement, or other report type, but specifically the voting results announcement.
2020-06-16 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 15, 2020, by IDEAYA Biosciences, Inc. It announces the entry into a material definitive agreement with GlaxoSmithKline (GSK) regarding a collaboration, option, and license agreement. The content details the terms of the agreement, including financial commitments, licensing rights, development responsibilities, and milestone payments. It also references a press release and a corporate presentation attached as exhibits. The document is not a full financial report, earnings release, or management discussion but rather a current report disclosing a significant business event (entry into a material definitive agreement). This fits the category of a current report announcing a material definitive agreement rather than a full annual or quarterly report or other categories. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP), as it relates to a significant financing and collaboration agreement involving capital commitments and strategic partnership terms.
2020-06-16 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.